Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Tavist offering

This article was originally published in The Tan Sheet

Executive Summary

Novartis Tavist NightTime Allergy provides "relief from sinus & nasal congestion, runny nose & sneezing" with an antihistamine "so you can rest," product labeling says. Line extension, which began hitting shelves in March, contains diphenhydramine 25 mg as an antihistamine, pseudoephedrine 60 mg as a nasal decongestant and is the only OTC positioned primarily for relief of nighttime allergy symptoms, Novartis says. Available in 24- and 48-count caplets for between $3.99 and $6.99, NightTime Allergy is the Tavist line's fourth offering. Product, which was originally named Tavist D/A, was slated to debut a year ago (1"The Tan Sheet" March 5, 2001, p. 5)...

You may also be interested in...



Tavist Line Extensions Include NDA, Monograph Products

Novartis Consumer Health is now shipping Tavist Allergy/Sinus/Headache following FDA approval of the firm's new drug application March 1.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel